Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/1995
06/07/1995CN1103316A Cyclodextrin and polymer-based drug delivery system
06/07/1995CN1103315A Improved methods for the determination and adjustment of prolactin daily rhythms
06/07/1995CN1103295A Oral nutrient ribonucleic acid liquid and its preparing method
06/07/1995CN1103294A "Kangle" three-in-one safety agent
06/07/1995CN1103293A Ethacridine use and method
06/07/1995CN1103292A Analgin nasal drops
06/07/1995CN1103291A Preparation for skin and mucous membrane
06/07/1995CN1103290A Pharmaceutical preparation
06/07/1995CN1103289A Opioid formulations having extended controlled release
06/07/1995CN1103288A Local anaesthetic and its preparing method
06/07/1995CN1028760C Process for preparing sequence of antidirection direction, antimessenger RNA oligonuclectides of alpha TNF
06/07/1995CN1028759C Substituted thiacycloalkeno |2,3-b¨ pyridines, method of preparation, compositions and method of use
06/07/1995CN1028758C Pyrazolopyrimidinone antianginal agents
06/07/1995CN1028757C Process for preparing heterocyclic derivatives
06/07/1995CN1028756C Pryidyl-and pyrimidyl derivatives
06/07/1995CN1028755C Azole derivate, manufacturing method and application thereof
06/07/1995CN1028754C Quinoline derivatives, their production and use
06/07/1995CA2137443A1 Thienothiazinderivatives, process for their preparation and their use
06/07/1995CA2137213A1 Imidazopyridines
06/06/1995US5422393 Natriuretic hormone
06/06/1995US5422374 Oral administration of ubidecarenone
06/06/1995US5422373 Anti-atherosclerotic aryl compounds
06/06/1995US5422372 Method of increasing intracellular accumulation of hydrophilic anionic agents using gemfibrizol
06/06/1995US5422371 Contacting a cell with a fatty acid or fatty alcohol to prevent reduction of testosterone to 5a-dihydrotestosterone
06/06/1995US5422370 Method of using 2-hydroxypropanoic acid (lactic acid) for the treatment of wrinkles
06/06/1995US5422369 Topical treatment
06/06/1995US5422368 With omega chain having a ring as end group, side effect reduction
06/06/1995US5422367 Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents
06/06/1995US5422366 Forming oxygen-scavenging metal chelate or metal complex-containing film over nail to deprive aerobic fungi of oxygen
06/06/1995US5422365 Naphthalene compounds
06/06/1995US5422363 Therapy of cancer, diabetes and vision disorders
06/06/1995US5422362 Method to inhibit restenosis
06/06/1995US5422359 α-aminoketone derivatives
06/06/1995US5422358 Muscarinic receptor antagonists
06/06/1995US5422357 Method of using oxatomide as antitussive agent
06/06/1995US5422355 Composition for treating depression with (N-heteroaryl)alkylamines
06/06/1995US5422354 Quinuclidine derivatives
06/06/1995US5422353 Tetrahydropyridine derivatives
06/06/1995US5422352 Administering a thermogenically effective dose of ephedrine and caffeine to reduce weight in humans
06/06/1995US5422351 Antiallergens; antiinflammatory agents
06/06/1995US5422350 Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
06/06/1995US5422349 Renin inhibitors
06/06/1995US5422347 Fungicides, hair and skin disorders
06/06/1995US5422346 Evaporative concentration to adjust degree of polymerization of pressed and assayed juice having cold water solubility and free from sesquiterpene lactones
06/06/1995US5422345 Useful in diagnosing or treating herpes viral infections
06/06/1995US5422344 Method of treating retroviral infections in mammals
06/06/1995US5422343 Prophylactic and therapeutic composition for MRSA infection
06/06/1995US5422342 A hydrolase inhibitor comprising a protected oligopeptides for treating fibrose of lungs, liver and skins, atherosclerosis
06/06/1995US5422124 Pharmaceutical oral controlled release composition comprising small pellets of bile acids
06/06/1995US5422119 Alternating dominance of estrogen and progestin in a patch regimen therapy to females; menopause
06/06/1995US5422115 Methods of treatment and devices employing lithium salts
06/06/1995US5422103 Wound healing agents for burns, bed sores; blended with dextran
06/06/1995US5422102 Diclofenac or salt with nonionic polymer of hydroxypropyl and/or hydroxyethyl cellulose; percutaneous adsorption
06/06/1995US5422101 Cholesterol lowering drink mix compositions
06/06/1995US5422100 Method and product for treating skin afflictions
06/06/1995US5422099 Compositions comprising vitamin D precursors and the use thereof
06/06/1995US5422093 Administering to produce protoporphyrin IX which accumulates in rapidly growing cells and fluoresces after exposure to light; anticarcinogenic and -tumor agents; urogenital disorders
06/06/1995US5421819 Medical probe device
06/06/1995CA2044795C Dermatological composition based on an aqueous phase
06/06/1995CA1335858C Polyanhydrides with improved hydrolytic degradation properties
06/06/1995CA1335816C 4-pyridyl-1,3-dioxan-5-ylalkenoic acid derivatives
06/06/1995CA1335813C Administration of monoamine acridines in cholinergic neuronal deficit states
06/06/1995CA1335789C Fatty acid compositions
06/06/1995CA1335788C Protein absorption enhancing agents
06/04/1995CA2137186A1 Erythromycine derivatives, a process for their preparation and use as drugs
06/04/1995CA2137029A1 Novel compounds
06/04/1995CA2137028A1 Pharmaceutical compounds
06/04/1995CA2136904A1 Excitatory amino acid receptor antagonists
06/04/1995CA2136569A1 Nutritional compositions for management of nitrogen metabolism
06/03/1995CA2136915A1 Substituted 2.beta.- morpholino-androstane derivatives
06/03/1995CA2135088A1 Liver protectant composition
06/02/1995CA2136789A1 Methods of inhibiting the effects of amyloidogenic proteins
06/01/1995WO1995014791A1 Design of drugs involving receptor-ligand-dna interactions
06/01/1995WO1995014777A1 p53-BINDING POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME
06/01/1995WO1995014709A1 Side chain fluoro substituted 3-carboxysteroids
06/01/1995WO1995014707A1 N-2 substituted purines
06/01/1995WO1995014706A1 Pna-dna-pna chimeric macromolecules
06/01/1995WO1995014697A1 Heterocyclic esters of rapamycin and pharmaceutical compositions containing them
06/01/1995WO1995014696A1 Hindered esters of rapamycin and their use as pharmaceuticals
06/01/1995WO1995014695A1 Novel furanodiazepines
06/01/1995WO1995014694A1 Benzodiazepines
06/01/1995WO1995014693A1 Imidazolinobenzodiazepines
06/01/1995WO1995014691A1 NOVEL 9-HYDROXY-PYRIDO[1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES
06/01/1995WO1995014687A1 Novel substituted thiosemicarbazonic acid esters
06/01/1995WO1995014686A1 Novel substitued thiosemicarbazonethiones
06/01/1995WO1995014685A1 Novel substituted thiosemicarbazone derivatives
06/01/1995WO1995014684A1 Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
06/01/1995WO1995014683A1 Novel isoxazoline and isoxazole fibrinogen receptor antagonists
06/01/1995WO1995014682A1 Isoxazoline compounds useful as fibrinogen receptor antagonists
06/01/1995WO1995014681A1 Isoxazoline compounds as antiinflammatory agents
06/01/1995WO1995014680A1 3-aryl-2-isoxazolines as antiinflammatory agents
06/01/1995WO1995014676A1 3-acylaminobenzodiazepines
06/01/1995WO1995014673A1 4,5-diphenylimidazole derivatives, their preparation and their use as acyl coenzyme a: cholesterol-0-acyl-transferase (acat) inhibitor
06/01/1995WO1995014671A1 3-acylaminobenzazepines
06/01/1995WO1995014670A1 Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action
06/01/1995WO1995014669A1 Novel benzenesulfonylimine derivatives as inhibitors of il-1 action
06/01/1995WO1995014667A1 Substituted indoles as phosphodiesterase type iv inhibitors
06/01/1995WO1995014666A1 Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
06/01/1995WO1995014662A1 26,28-methylene-1alpha,25-dihydroxyvitamin d2 compounds
06/01/1995WO1995014657A1 Alpha-aryl or heteroaryl-substituted amide ester acat inhibitors